MET and non-small cell lung carcinoma: Many receptor tyrosine kinases (RTKs) have been identified in NSCLC tumor samples and may act as a bypass activation of the EGFR signaling pathway in NSCLC, such as Met and IGF‐1R.[16] Previous studies have shown that fibroblast growth factor receptor 1 (FGFR1), a typical RTKs, is overexpressed in various types of human cancers, including 20% of NSCLC.